Screener
Idexx Laboratories IDXX Asset write-downs
Asset write-downs at other companies
Other financials
Where this comes from
Reported directly by Idexx Laboratories in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Idexx Laboratories’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:14 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000874716-26-000076
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Net income | $278,446 | $242,677 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 37,683 | 34,063 |
| Impairment charge | 5,000 | — |
| Provision for credit losses | 3,942 | 2,890 |
| Deferred income taxes | 13,890 | 3,948 |
| Share-based compensation expense | 16,340 | 14,615 |
| Other | 695 | 456 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Idexx Laboratories's asset write-downs?
- Idexx Laboratories (IDXX) reported asset write-downs of $5M in Q1 2026.
Ask your AI about Idexx Laboratories's asset write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude